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Cytosol from untreated cells and a detergent extract of the particulate fraction from TPA-treated HL-60 cells were ana- 
lyzed for protein kinase C activity by consecutive column chromatography on Mono Q and hydroxyapatite. From both 
preparations two separate peaks of enzyme activity were obtained. The first peak, eluting at lower salt concentrations, 
is activated at lower TPA concentrations (3 x 10 4 M) than the other (10 -7 M), which was eluted at higher salt concentra- 
tions. 
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1. INTRODUCTION 
The human promyelocytic cell line HL-60 can be 
induced to differentiate o macrophage-like cells by 
treatment with the tumor-promoting phorbol ester 
12-O-tetradecanoyl phorbol 13-acetate (TPA) 
[1,2]. Protein kinase C (PKC), the putative recep- 
tor for TPA [3-5], is part of a cascade of second 
messengers esulting from phosphoinositide turn- 
over. Hydrolysis of PIP2 in response to a trans- 
membrane signal, e.g. growth factor, leads to the 
formation of IP3 and diacylglycerol (DAG) [6]. IP3 
stimulates the release of calcium from internal 
stores, whereas DAG activates PKC and causes 
translocation of PKC from cytosol to the mem- 
brane [7]. TPA can mimick DAG in activating 
PKC. 
PKC comprises a family of serine/threonine- 
specific protein kinases. Thus far, a number of sub- 
species (or, flI/II, 7 [8] and ~, c, ~ [9]) have been 
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identified by molecular cloning. Separation of 
PKC from mouse brain cytosol into two subtypes 
on a hydroxyapatite column was reported by 
Schmidt and Hecker [10]. 
Here, the separation of PKC activity from un- 
treated and TPA-treated HL-60 cells into two PKC 
subtypes on hydroxyapatite column chromatog- 
raphy and their different activation by TPA are 
described. 
2. MATERIALS AND METHODS 
2.1. Chemicals 
[7)2p]ATP (spec. act. 2-10 Ci/mmol) was obtained from 
NEN Research Products, Boston. Chemicals of analytical or 
purest obtainable grade were from Sigma, Taufkirchen. 
Materials for cell culture were from Boehringer Mannheim and 
Gibco (Eggenstein, FRG). 
2.2. Cell culture 
HL-60 ceils obtained from Dr Braun (Institute of Im- 
munology, Heidelberg) were grown in RPMI 1640 medium sup- 
plernented with 10°70 fetal calf serum, 1070 glutamine and 
penicillin (100 U/ml)/streptomycin (10/zg/ml) and incubated at 
37°C in an atmosphere of 5% CO2. Cells were seeded at a densi- 
ty of 3 × 105 cells/ml and grown for 3 days. Treatment of ceils 
with TPA was performed by addition from a stock solution of 
10 -4 M TPA in acetone to a final concentration of 10 -7 M, 
30 rain before cells were harvested. 
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2.3. Preparation of cytosol and particulate fractions 
Cells were centrifuged, washed with cold PBS, resuspended in 
homogenization buffer (10 mM EGTA, 5 mM EDTA, 2 mM 
DTE, 20 mM Tris, 0.1 mM PMSF, 10/~g/ml leupeptin) and 
disrupted with a Dounce homogenizer (tight fitting pestle). The 
homogenate was centrifuged at 110000 x g for 60 min at 2°C. 
The supernatant was used as the cytosol fraction. The pellet was 
resuspended in homogenization buffer containing 0.5% Triton 
X-100 and rehomogenized using the Dounce homogenizer. 
After centrifugation at 110000 × g for 60 rain, the resulting 
supernatant was used as the extract of the membrane fraction 
(Detergent extract) for further purification by chromatography. 
2.4. Mono Q anion-exchange column 
Cytosol and detergent extracts of the particulate fraction were 
analyzed by chromatography at 2°C on a Mono Q column 
(Pharmacia, Freiburg) equilibrated in buffer A (20 mM Tris, 
2 mM EDTA, 2 mM DTE). PKC activity was eluted with a 
linear gradient of 0-500 mM NaC1 (30 ml). 1-ml fractions were 
collected• 
2.5. Hydroxyapatite column 
Pooled fractions from the Mono Q column containing PKC 
activity were applied to a hydroxyapatite column (HPHT, Bio- 
Rad, Munich) equilibrated at 2°C in buffer B (10 mM 
potassium phosphate, 0.3 mM CaCl2, 2 mM DTE, 0.1 mM 
PMSF, 1/~g/ml leupeptin) and enzyme activity was eluted with 
a linear gradient of 10-500 mM potassium phosphate (high-sait 
buffer containing 2/~M CaC12). 1-ml fractions were collected. 
2.6. PKC assay 
PKC activity was detected by measuring the incorporation of
phosphate from [7-32p]ATP into histone. The assay mixture 
(125/~l) consisted of histone type III (Sigma no. H-5505) at 
240/Lg/ml, 4 mM MgC12, 50 mM mercaptoethanol, 180/zg/ml 
phosphatidylserine a d1 mM EGTA. 10-/A aliquots of each col- 
umn fraction were used. TPA was used at a final concentration 
of 10 -7 M; [7-32P]ATP was at 20/zM. The mixture was in- 
cubated for 10 min at 30°C, aliquots of 50/zl spotted onto phos- 
phocellulose paper sheets (P81 Whatman, Bender und Hobein, 
Munich), washed with four changes of water, then acetone and 
petroleum ether and counted in a liquid scintillation counter. 
2.7. Dose-response experiments 
PKC was assayed as described in section 2.6 with the excep- 
tion that TPA was added in final concentrations from 10 -1° to 
10 -6 M. 
3. RESULTS 
3.1. Distribution of  PKC in HL-60 cells 
Under the conditions of homogenization 
described in section 2, PKC activity in untreated 
cells was found almost exclusively in the cytosolic 
fraction. It eluted from Mono Q at salt concentra- 
tions between 150 and 180 mM NaC1. Treatment 
of HL-60 cells with 10-7M TPA for 30 min 
resulted in almost complete translocation of PKC 
activity from the cytosol to the particulate fraction 
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Fig. 1. PKC profile on hydroxyapatite column of cytosol from 
untreated HL-60 cells. Pooled PKC activity [determined as 
described in section 2; ( ) TPA, ( - - - )  acetone control[ 
from the Mono Q gradient were loaded on the column and en- 
zyme activity was eluted with a linear gradient of 10-500 mM 
potassium phosphate [gradient: ( ) nominal, ( . . . . .  ) deter- 
mined with conduct•meter]. No enzyme activity was found in 
the isocratic wash. 
3.2. PKC subtypes on hydroxyapatite column 
chromatography 
PKC activity from untreated as well as TPA- 
treated cells pooled from a Mono Q gradient and 
analyzed on a hydroxyapatite column consistently 
showed two peaks of enzyme activity. The first 
peak appeared at salt concentrations between 120 
and 140 mM, the other at 160-200 mM phosphate 
(fig.l), 
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Fig.2. Dose-response curve for activation by TPA of PKC sub- 
types [peak 1 ( ), peak 2 ( -  - - ) l  from cytosol of untreated 
cells (O) and detergent extract of particulate fraction of TPA- 
treated HL-60 cells (©). TPA was tested in the range 
10-~°-10-6 M. Enzyme activity is expressed in percent of the ac- 
tivity at 10 -7 M TPA which is taken as 100%. Data are shown 
for one out of two experiments with comparable r sults. 
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3.3. Dose response of PKC activation by TPA 
In fig.2, typical dose-response curves for 
separated PKC activity from cytosol of  untreated 
HI-60 cells by TPA are shown. Peak l (eluting at 
lower salt) is maximally activated at lower TPA 
concentrations (3 x 10 -9 M) than peak 2 (10 -7 M). 
The same results were obtained for the two PKC 
subtypes from the detergent extract of  the par- 
ticulate fraction from TPA-treated cells (fig.2). 
the two PKC subtypes, their activation and en- 
dogenous ubstrates depending on different stimuli 
(e.g., TPA,  OAG and bryostatin). 
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